• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 3. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

Professional Introduction to 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde (CAS No. 1258636-35-9)

2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde, with the CAS number 1258636-35-9, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the class of benzaldehyde derivatives, characterized by its hydroxy and trifluoromethoxy functional groups, which contribute to its unique chemical properties and potential biological activities.

The structural motif of 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde positions it as a promising candidate for further investigation in drug discovery and development. The presence of a hydroxyl group at the 2-position and a trifluoromethoxy group at the 3-position of the benzene ring introduces both polar and electron-withdrawing effects, which can modulate its interactions with biological targets. Such structural features are often exploited in the design of bioactive molecules due to their ability to influence solubility, metabolic stability, and binding affinity.

In recent years, there has been a growing interest in exploring the pharmacological potential of benzaldehyde derivatives. These compounds have shown promise in various therapeutic areas, including anti-inflammatory, antimicrobial, and anticancer applications. The specific arrangement of functional groups in 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde suggests that it may exhibit unique mechanisms of action compared to other benzaldehyde-based scaffolds.

One of the most compelling aspects of this compound is its potential as a precursor in the synthesis of more complex pharmacophores. The aldehyde functionality provides a reactive site for further chemical modifications, allowing chemists to explore diverse structural variations. This flexibility is crucial in medicinal chemistry, where subtle changes in molecular structure can significantly impact biological activity. Researchers have been particularly interested in how the trifluoromethoxy group influences electronic properties and potential interactions with biological targets.

Recent studies have begun to unravel the biological significance of trifluoromethoxy-substituted aromatic compounds. The electron-withdrawing nature of the trifluoromethoxy group can enhance binding affinity by modulating charge distribution and improving hydrophobic interactions. Additionally, this group is known to increase metabolic stability, a critical factor in drug design aimed at prolonging half-life and improving bioavailability. The hydroxyl group further contributes to hydrogen bonding capabilities, which can be exploited for receptor binding.

The synthesis of 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde involves multi-step organic transformations that highlight its synthetic accessibility while maintaining structural complexity. Advanced synthetic methodologies have been employed to ensure high yield and purity, making it a viable candidate for further pharmacological evaluation. Techniques such as palladium-catalyzed cross-coupling reactions and selective functional group transformations have been instrumental in constructing this intricate molecular framework.

In the context of drug discovery, 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde has been investigated for its potential role in modulating inflammatory pathways. In vitro studies have suggested that derivatives of this compound may interact with enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are key players in inflammation. The presence of both hydroxyl and aldehyde groups provides multiple sites for interaction with these enzymes, potentially leading to novel anti-inflammatory agents.

The impact of fluorine atoms on biological activity cannot be overstated. Fluoro-substituted compounds are widely recognized for their enhanced pharmacological properties, including improved binding affinity and metabolic stability. The trifluoromethoxy group in 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde is no exception, offering a strategic tool for fine-tuning molecular interactions. This has led to increased interest in developing fluorinated benzaldehyde derivatives as lead compounds for therapeutic intervention.

Evaluation of 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde also extends to its potential anticancer applications. Preliminary data indicate that benzaldehyde derivatives can induce apoptosis and inhibit proliferation in various cancer cell lines. The specific structural features of this compound may enhance its ability to interact with oncogenic pathways, making it a valuable candidate for further preclinical studies. The combination of hydroxyl and trifluoromethoxy groups may provide synergistic effects that improve therapeutic outcomes.

The role of computational chemistry in studying compounds like 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde cannot be ignored. Molecular modeling techniques have been employed to predict binding modes and affinity for various biological targets. These simulations provide insights into how structural modifications can optimize pharmacological activity, guiding experimental design with greater precision. Such integrative approaches are becoming increasingly essential in modern drug discovery pipelines.

The future prospects for 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde are promising, with ongoing research aimed at expanding its therapeutic applications. Further investigation into its mechanism of action will be crucial for understanding its full potential as a pharmacological agent. Collaborative efforts between synthetic chemists and biologists will be essential in translating laboratory findings into clinical applications.

In conclusion, 2-hydroxy-3-[3-(trifluoromethoxy)phenyl]benzaldehyde (CAS No. 1258636-35-9) represents an exciting avenue for exploration in pharmaceutical chemistry. Its unique structural features offer multiple opportunities for designing novel therapeutic agents with potential applications ranging from anti-inflammatory to anticancer treatments. As research continues to uncover new biological activities associated with benzaldehyde derivatives, compounds like this will play an increasingly important role in addressing unmet medical needs.

• 94651-33-9(2-(Trifluoromethoxy)benzaldehyde)
• 1191039-22-1(2-hydroxy-3-[4-(trifluoromethoxy)phenyl]benzaldehyde)
• 93249-62-8(2-Hydroxy-5-(trifluoromethoxy)benzaldehyde)
• 1018959-57-3(2-hydroxy-5-[4-(trifluoromethoxy)phenyl]benzaldehyde)
• 1111129-39-5(2-hydroxy-5-[3-(trifluoromethoxy)phenyl]benzaldehyde)
• 675596-34-6(4'-TRIFLUOROMETHOXY-BIPHENYL-3-CARBALDEHYDE)
• 145742-65-0(2-Methoxy-5-(trifluoromethoxy)benzaldehyde)
• 1191053-35-6(2-hydroxy-4-[4-(trifluoromethoxy)phenyl]benzaldehyde)
• 1261966-87-3(2-hydroxy-4-[3-(trifluoromethoxy)phenyl]benzaldehyde)
• 398156-35-9(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-carbaldehyde)